Loading…
AMN Healthcare Services, Inc. provides technology-enabled healthcare workforce solutions and staffing services to acute and sub-acute care hospitals, and other healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. It offers travel nurse staffing, labor disruption staffing, local staffing, international nurse permanent placement, allied staffing, crisis nurse staffing for critical staffing and rapid response nursing, and allied health professionals, such as skilled nursing facilities, rehabilitation clinics, schools, and pharmacies, as well as physician and advanced practice staffing, and revenue cycle solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists; and solutions for schools, including teletherapy platform, Televate, and qualified school speech-language pathologists, psychologists, nurses, social workers, and other care providers. In addition, it offers locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. Additionally, the company provides language services, vendor management systems, workforce optimization, and outsourced solutions. The company offers its services under the brands, including AMN Healthcare, Nursefinders, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is based in Dallas, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2.7B | $101M | $-96M | $234M | -14.9% | -8.5% | -34.9% |
| 2024 | $3.0B | $71M | $-147M | $240M | -20.8% | -21.3% | -169.8% |
| 2023 | $3.8B | $499M | $211M | $267M | 25.3% | -27.7% | -52.6% |
| 2022 | $5.2B | $784M | $444M | $573M | 42.5% | - | - |
| 2021 |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 5,243.24 | 3,789.25 | 2,983.78 | 2,730.43 |
| Operating Revenue | - | 5,243.24 | 3,789.25 | 2,983.78 | 2,730.43 |
| Cost Of Revenue | - | 3,526.56 | 2,539.67 | 2,064.41 | 1,956.37 |
| Gross Profit | - | 1,716.68 | 1,249.58 | 919.38 | 774.06 |
| Operating Expense | - | 1,069.58 | 903.35 | 799.59 | 740.89 |
| Selling General And Administration | - | 936.58 | 748.44 | 632.49 | 593.02 |
| Total Expenses | - | 4,596.14 | 3,443.02 | 2,864 | 2,697.26 |
| Operating Income | - | 647.10 | 346.23 | 119.78 | 33.17 |
| Total Operating Income As Reported | - | 647.10 | 338.43 | -102.67 | -55.47 |
| EBITDA | - | 784.21 | 499.36 | 71.11 | 101.13 |
| Normalized EBITDA | - | 784.21 | 507.16 | 293.56 | 189.77 |
| EBIT | - | 647.10 | 338.43 | -102.67 | -55.47 |
| Interest Expense | - | 40.40 | 54.14 | 69.90 | 45.59 |
| Net Interest Income | - | -40.40 | -54.14 | -69.90 | -45.59 |
| Other Income Expense | - | - | -7.80 | -222.46 | -88.64 |
| Interest Expense Non Operating | - | 40.40 | 54.14 | 69.90 | 45.59 |
| Net Non Operating Interest Income Expense | - | -40.40 | -54.14 | -69.90 | -45.59 |
| Pretax Income | - | 606.70 | 284.29 | -172.57 | -101.06 |
| Tax Provision | - | 162.65 | 73.61 | -25.60 | -5.36 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | -2.02 | -32.99 | -4.70 |
| Net Income Continuous Operations | - | 444.05 | 210.68 | -146.98 | -95.70 |
| Net Income From Continuing And Discontinued Operation | - | 444.05 | 210.68 | -146.98 | -95.70 |
| Net Income From Continuing Operation Net Minority Interest | - | 444.05 | 210.68 | -146.98 | -95.70 |
| Net Income | - | 444.05 | 210.68 | -146.98 | -95.70 |
| Net Income Common Stockholders | - | 444.05 | 210.68 | -146.98 | -95.70 |
| Net Income Including Noncontrolling Interests | - | 444.05 | 210.68 | -146.98 | -95.70 |
| Normalized Income | - | 444.05 | 216.46 | 42.48 | -11.76 |
| Diluted NI Availto Com Stockholders | - | 444.05 | 210.68 | -146.98 | -95.70 |
| Basic Average Shares | - | 44.59 | 39.17 | 38.19 | 38.52 |
| Diluted Average Shares | - | 44.87 | 39.34 | 38.19 | 38.52 |
| Reconciled Depreciation | - | 137.11 | 160.93 | 173.78 | 156.60 |
| Reconciled Cost Of Revenue | - | 3,522.45 | 2,533.66 | 2,057.73 | 1,947.64 |
| Total Unusual Items | - | 0 | -7.80 | -222.46 | -88.64 |
| Total Unusual Items Excluding Goodwill | - | 0 | -7.80 | -222.46 | -88.64 |
| Special Income Charges | - | 0 | -7.80 | -222.46 | -88.64 |
| Impairment Of Capital Assets | - | 0 | 7.80 | 222.46 | 127.78 |
| Depreciation Amortization Depletion Income Statement | - | 133.01 | 154.91 | 167.10 | 147.87 |
| Depreciation And Amortization In Income Statement | - | 133.01 | 154.91 | 167.10 | 147.87 |
| General And Administrative Expense | - | 936.58 | 756.24 | 632.49 | 593.02 |
| Other Gand A | - | 906.51 | 738.22 | 609.17 | 562.34 |
| Salaries And Wages | - | 30.07 | 18.02 | 23.32 | 30.68 |
| Gain On Sale Of Ppe | - | - | 0 | 0 | 39.14 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| AMN Healthcare Services, Inc.this co. | AMN | $1.2B | - | 1.85 | -14.9% | 19.35 |
| Inspire Medical Systems, Inc. | INSP | $1.2B | 8.36 | 1.56 | 18.6% | 14.32 |
| IRADIMED CORPORATION | IRMD | $1.2B | 53.21 | 12.64 | 23.8% | 41.92 |
| CareDx, Inc. | CDNA | $1.2B | -55.93 | 3.94 | -7.0% | -248.15 |
| Kestra Medical Technologies, Ltd. | KMTS |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $1.2B |
| -10.49 |
| 5.81 |
| -55.4% |
| -10.21 |
| Schrödinger, Inc. | SDGR | $1.2B | -11.47 | 3.25 | -28.4% | -6.61 |
| Wave Life Sciences Ltd. | WVE | $1.2B | - | 2.26 | -39.4% | - |
| Avanos Medical, Inc. | AVNS | $1.2B | - | 1.50 | -9.4% | - |
| Zenas BioPharma, Inc. | ZBIO | $1.2B | -3.07 | 4.79 | -156.0% | -2.84 |
| Peer Median | - | -6.78 | 3.60 | -18.9% | -4.72 | |